# Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma

> **NCT00350961** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 39 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00350961
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2008-02
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2008-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350961, "Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00350961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*